文献速递心律失常

低负荷房颤患者的抗凝治疗:聚焦设备检测房颤的新证据

Anticoagulation in patients with low-burden atrial fibrillation: new evidence focussing on device-detected AF.
PubMed 文献 · Heart · 2025-10-14

综述探讨房颤负荷对卒中风险的调控作用,指出心电图确诊房颤患者抗凝仍是默认治疗,而节律控制减少房颤负荷成为卒中预防新策略。设备检测房颤(DDAF)且无心电图确诊房颤和血管疾病的患者血栓栓塞风险低,此类患者需共享决策,考虑血管疾病、极高房颤负荷及患者偏好。

要点

  • 心电图确诊房颤且合并临床卒中危险因素者,口服抗凝仍为默认治疗。
  • 减少房颤负荷的节律控制治疗成为卒中预防的新策略。
  • DDAF且无心电图确诊房颤和血管疾病者血栓栓塞风险低,抗凝获益可能不抵风险。

核心结论

  • 房颤负荷调控卒中风险,心电图确诊房颤患者抗凝仍是默认治疗,而低负荷如DDAF患者可能风险获益比不利。

研究设计与样本

  • 综述,基于近期对照试验与观察性数据,讨论低负荷房颤的抗凝策略。

主要发现

  • 对照试验中筛查检测房颤的卒中率略低于预期,DDAF患者及房颤消融后卒中率显著低于预期。
  • 观察性数据显示心电图确诊房颤患者房颤负荷高,支持抗凝作为默认治疗。
  • DDAF且无心电图确诊房颤和血管疾病者血栓栓塞事件风险低。

临床怎么用

  • 心电图确诊房颤患者维持口服抗凝作为默认治疗。
  • DDAF患者采用共享决策,考虑血管疾病、极高房颤负荷及患者偏好。
  • 节律控制减少房颤负荷可作为卒中预防的新策略。

局限性

  • 需更多数据才能稳健定义房颤负荷、表型与卒中风险之间的复杂关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, one of the most severe complications of atrial fibrillation (AF), can be prevented by oral anticoagulants in patients with ECG-documented AF and clinical stroke risk factors. Recent controlled trials suggest that reducing the burden of AF, that is, the time spent in AF, can reduce the risk of stroke. Furthermore, stroke rate was slightly lower than anticipated in controlled trials of anticoagulation in screening-detected AF, and substantially lower than expected in patients with device-detected atrial fibrillation (DDAF) and after AF ablation. These data suggest that AF burden modulates the risk of stroke in patients with AF. Based on their high AF burden in observational datasets, anticoagulation remains the default therapy in patients with ECG-documented AF. However, AF burden reduction using rhythm-control therapies emerges as a new treatment strategy for stroke prevention, and there may be a group of patients with such a low burden of AF, for example, patients with DDAF, that the risks of current anticoagulation therapies outweigh their stroke-preventing effects. Patients with DDAF in the absence of ECG-documented AF and without vascular disease appear to be at low risk of thromboembolic events. In patients with DDAF, shared decision-making that considers the presence of vascular disease, potentially the burden of AF if it is very high, and patient preferences currently emerges as good clinical care. More data are needed to robustly define the complex relations between AF burden, phenotypes and stroke risk.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Becher, Metzner, Kirchhof, et al. Anticoagulation in patients with low-burden atrial fibrillation: new evidence focussing on device-detected AF. Heart. 2025. PMID: 40306759. doi:10.1136/heartjnl-2024-324848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。